<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140396</url>
  </required_header>
  <id_info>
    <org_study_id>53087</org_study_id>
    <nct_id>NCT04140396</nct_id>
  </id_info>
  <brief_title>Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia</brief_title>
  <official_title>A Prospective Comparison of Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current cornerstone of pain control for rib fractures is oral and intravenous opioids,
      especially in the form of patient-controlled analgesia (IV PCA), which are are associated
      with multiple adverse effects including sedation, respiratory depression, cough suppression,
      and increased risk of delirium.

      In the past few decades, intravenous lidocaine infusion (IVL) has emerged as a new tool in
      the arsenal of multimodal analgesia. Multiple randomized clinical trials have indicated that
      IVL is overall well tolerated and have shown other beneficial effects such as
      anti-inflammatory properties. To this date, there have been no published randomized clinical
      trials (RCT) evaluating the effectiveness of IVL in management of traumatic rib fracture
      pain.

      Therefore, the purpose of this study is to evaluate whether IV Lidocaine infusion can provide
      improved pain control as demonstrated by decreased OME consumption at 24 and 48 hours
      compared to placebo in adult patients with acute traumatic rib fractures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OME consumption at 24 hours</measure>
    <time_frame>After 24 hours of treatment</time_frame>
    <description>oral morphine equivalent consumption at 24 hours of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OME at 48 hrs</measure>
    <time_frame>After 48 hours of treatment</time_frame>
    <description>oral morphine equivalent consumption at 48 hours of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Every 4 hours general pain scores, and baseline, 24 hours, 48 hour, 72 hours for pain scores with cough and inspiration.</time_frame>
    <description>Pain scores at rest and with cough and deep inspiration. Will use Numeric Rating Scale (NRS) of 0-10, where 0 is no pain and 10 is the worst imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incentive spirometry volumes</measure>
    <time_frame>Time 0, 24 hours, 48 hour, and 72 hours.</time_frame>
    <description>An incentive spirometer is a device that measures how deeply you can inhale. Higher volumes indicate greater ability to inhale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIC score</measure>
    <time_frame>Time 0, 24 hours, 48 hour, and 72 hours.</time_frame>
    <description>PIC score is a composite score comprising pain level, ISV, and cough strength. PIC scores range from 1-10 with one being severe pain, inability to perform incentive spirometry, and absent cough and 10 being controlled pain, an incentive spirometry volume above goal volume(set by respiratory therapist), and strong cough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>We will record the number of days stayed at the hospital from the day of operation till the day of discharge (from 0-10, or 10+)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory biomarkers</measure>
    <time_frame>Time 0, 24 hours, and 48 hour</time_frame>
    <description>Will be looking at proinflammatory markers (IL6, IL8, IL-1β, TNF-α) and f anti-inflammatory markers (IL10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of pulmonary complications</measure>
    <time_frame>Will be assessed up to 72 hours.</time_frame>
    <description>We will look at the occurrence of things like ARDS, pneumonia, aspiration, empyema, etc</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Rib Fractures</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo infusion consisting of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a lidocaine infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline infusion</intervention_name>
    <description>Normal saline infusion at 10mL/hour</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine infusion</intervention_name>
    <description>Lidocaine infusion at 1.0mg/kg/hr</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all adult patients admitted to Stanford Health Care with two or more acute traumatic
             rib fractures

        Exclusion Criteria:

          -  hemodynamically instability

          -  mechanical ventilation

          -  polytrauma (defined as bone or organ injury outside the thorax)

          -  pregnancy

          -  incarceration

          -  local anesthetic allergy or contraindications to lidocaine (Stokes-Adams syndrome,
             Wolff-Parkinson-White syndrome, or severe degrees of sinoatrial, atrioventricular, or
             intraventricular block)

          -  chronic opioid use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Healthcare</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ban Tsui, MD</last_name>
      <phone>650-200-9107</phone>
      <email>bantsui@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic indication? Anesthesiology. 2000 Sep;93(3):858-75. Review.</citation>
    <PMID>10969322</PMID>
  </reference>
  <reference>
    <citation>Flagel BT, Luchette FA, Reed RL, Esposito TJ, Davis KA, Santaniello JM, Gamelli RL. Half-a-dozen ribs: the breakpoint for mortality. Surgery. 2005 Oct;138(4):717-23; discussion 723-5.</citation>
    <PMID>16269301</PMID>
  </reference>
  <reference>
    <citation>Gordy S, Fabricant L, Ham B, Mullins R, Mayberry J. The contribution of rib fractures to chronic pain and disability. Am J Surg. 2014 May;207(5):659-62; discussion 662-3. doi: 10.1016/j.amjsurg.2013.12.012. Epub 2014 Jan 31.</citation>
    <PMID>24612969</PMID>
  </reference>
  <reference>
    <citation>Battle CE, Hutchings H, Evans PA. Risk factors that predict mortality in patients with blunt chest wall trauma: a systematic review and meta-analysis. Injury. 2012 Jan;43(1):8-17. doi: 10.1016/j.injury.2011.01.004. Epub 2011 Jan 22. Review.</citation>
    <PMID>21256488</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Chi-Ho Ban Tsui</investigator_full_name>
    <investigator_title>Professor of Anesthesiology, Perioperative and Pain Medicine, Stanford University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

